BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 28459468)

  • 1. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
    Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
    Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
    Ziemke EK; Dosch JS; Maust JD; Shettigar A; Sen A; Welling TH; Hardiman KM; Sebolt-Leopold JS
    Clin Cancer Res; 2016 Jan; 22(2):405-14. PubMed ID: 26369631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer.
    Rampioni Vinciguerra GL; Dall'Acqua A; Segatto I; Mattevi MC; Russo F; Favero A; Cirombella R; Mungo G; Viotto D; Karimbayli J; Pesce M; Vecchione A; Belletti B; Baldassarre G
    Cell Death Dis; 2021 Oct; 12(10):951. PubMed ID: 34654798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
    Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
    Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
    Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
    Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
    Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
    Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
    Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
    Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
    de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE
    Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788
    [No Abstract]   [Full Text] [Related]  

  • 13. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
    Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
    BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
    Nassar KW; Hintzsche JD; Bagby SM; Espinoza V; Langouët-Astrié C; Amato CM; Chimed TS; Fujita M; Robinson W; Tan AC; Schweppe RE
    Mol Cancer Ther; 2021 Oct; 20(10):2049-2060. PubMed ID: 34376578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
    Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
    Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Dec; 38(1):492. PubMed ID: 31842958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
    Zhao M; Scott S; Evans KW; Yuca E; Saridogan T; Zheng X; Wang H; Korkut A; Cruz Pico CX; Demirhan M; Kirby B; Kopetz S; Diala I; Lalani AS; Piha-Paul S; Meric-Bernstam F
    Clin Cancer Res; 2021 Mar; 27(6):1681-1694. PubMed ID: 33414137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
    Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
    Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
    Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.